GENCLIS SA is a privately-held French Biotechnology that discovered a unique biological mechanism referred as to Transcription Infidelity (TI).
Transcription Infidelity is a newly discovered and patented mechanism that incresases RNA-DNA sequence divergences (RDD). TI can lead to base substitutions, insertions and deletions. The latter cause translational frameshifts that have important consequences in determining protein immunogenicity. Genclis currently focuses on defining the effects of TI proteins translated from gapped RNA on normal and pathological humoral immunity.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 15, Rue Du Bois De La Champelle, Vandoeuvre-Lès-Nancy,grand Est 54500,france
- Phone
- +33 3 83 67 82 11
- in****@****lis.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- genclis.com
- HQ
- Vandoeuvre-lès-Nancy, Grand Est
Genclis Sa Questions
Genclis Sa's helpline number is +33 3 83 67 82 11
Genclis Sa's website is genclis.com
Genclis Sa's LinkedIn profile is https://fr.linkedin.com/company/genclis-sa
Genclis Sa has
6 employees.
View email and phone details for 6
employees at Genclis Sa.
Genclis Sa's industry is
Biotechnology Research
Genclis Sa's top competitors are
Tronico,
Discngine,
Tfs Healthscience,
Depixus,
Vera Therapeutics, Inc.,
Mundipharma.
Genclis Sa's support email address is info@genclis.com
Genclis Sa's categories are Biotechnology Research
Genclis Sa's founding year is 2004
